巻号一覧
45 巻, 1 号
選択された号の論文の5件中1～5を表示しています
- |<
- <
- 1
- >
- >|
-
第19報その実際的意義と対策に関する研究6.1回のツベルクリン反応の影響の持続期間について(続報)松島 正視1970 年 45 巻 1 号 p. 1-11
発行日: 1970年
公開日: 2011/05/24
ジャーナル フリーThe pattern of tuberculin reaction is altered when the injection is made on the site of previous test. Remarkable reaction appears as early as three to four hours after the injection (early reaction). The reaction attains its maximum after 12 to 24 hours, and thereaf ter, it declines markedly (acceleration of the delayed reaction). After 48 hours, induration is hardly perceptible in many cases.抄録全体を表示PDF形式でダウンロード (2905K) -
第20報促進現象の発現機序に関する研究5.サルコイドーシス患児におけるツ反応反復松島 正視, 戸所 正雄, 寺尾 宏一郎, 宮下 晴夫, 木村 利定1970 年 45 巻 1 号 p. 13-17
発行日: 1970年
公開日: 2011/05/24
ジャーナル フリーIn the skin area in which a tuberculin test was previously given (the used site), the reaction pattern is altered. Namely, the early reaction is elicited and the course of the delayed reaction is accelerated. In the preceeding studies it was proved that the alteration of the reaction pattern at the previously used site is the result of the local sensitization which is caused by the injection of tuberculin protein into a tuberculin sensitive person.
In the case of sarcoidosis, the systemic tuberculin sensitivity is d epressed. A possible explanation of this phenomenon is the depressed production of the sort of antibodies which participate in the delayed reactions and are contained in circulating lymphocytes.
This study was made to investigate the local tuberculin sensitivity at the used site among sarcoidosis patients, whose systemic tuberculin sensitivity was depressed.
Nine sarcoidosis patients, aged 7 years and 8 months to 14 y ears and 9 months, who were all tuberculin positive before the onset of the disease (Table 1), were injected with 5 TU Old Tuberculin in two sites, namely, the upper one third of the left forearm where tuberculin had been previously injected (the used site) and the lower one third of the upper arm where tuberculin had never been injected (the new site). Reactions were observed 4, (8, 12), 24 and 48 hours after the injection (Table 2, Figure 1).
In two out of nine patients, the delayed re a ction at the new site was positive (erythema with diameter over 10 mm). In the other seven patients the delayed reaction at the new site was negative (erythema with diameter under 4 mm) or doubtful (erythema with diameter 5-9mm). In one of them, neither the delayed reaction at the new site, nor the early reaction at the used site was observed. In the remaining six cases, definite early reaction was elicited at the used site. In three of them the reaction attenuated markedly after 24 hours and showed only small erythema with diameter under 6 mm. These reactions might be considered as early reaction without accompanying delayed reaction. In the other three patients the reaction continued for 24 hours, declined thereafter, and after 48 hours only a very pale erythema or pigmentation remained.
From these results it is likely that the antibody which elicits the local early reaction may differ from that which participate in the systemic delayed reaction and which is contained in circulating cells.抄録全体を表示PDF形式でダウンロード (442K) -
馬場 治賢, 吾妻 洋, 田島 洋, 宮田 ユキ, 佐野 豊子1970 年 45 巻 1 号 p. 19-26
発行日: 1970年
公開日: 2011/05/24
ジャーナル フリー1) During the past 6 years from Dec.1962 to Dec.1968, 421 cases of pulmonary tuberculosis patients were treated with ethambutol for 1 to 48 months (the average 11.9 months). During this period, 15 cases (3.57%) of visual impairment were experienced.
2) Except 11 cases originally treated, the majority of cases were resistant to SM and INH, and almost all cases were already treated with KM, TH, and CS. Dividing by the extent of pulmonary lesions according to NTA classification, 44% were far advanced, 47% were moderately advanced, and 44% of the cases were over 10 years since the onset of the disease.
3) As shown in Table 1, visual impairment occured rather suddenly from 54 day s to 23months after starting EB treatment. Consequently, there is no definite time for its onset, but all the cases except one case complained visual impairment before the periodic routine vision tests. This suggests that the frequent routine vision examination is not always necessary.
4) Visual impairment is the most remarkable symptom and many showed r apid, marked fall of the vision (Fig.1). Including 1 case which showed visual impairment 20 days after the cessation of EB, we experienced 7 cases which showed continuous downfall of the vision even after stopping EB. The visual impairment recovered within 2 months in 3 cases, but it required approximately 6 months in the other cases.
5) Visual field test showed the e nlargement of the blind spot and the relative central scotom in most of the cases. Out of 9 cases examined, 8 cases showed abnormal visual field (Fig.2).
6) 11 cases showed color blindness but all were temporarily.
7) Fundus examination showed pictures of acute r etrobulbar neuritis in half of the cases. The remaining 7 cases showed neuritis and retinitis and among them, 3 cases showed retinal hemorrhage (Fig.3). The fundus examination conducted on 147 cases treated by EB without any side-affects showed clearly that the above hemorrhage was characteristic (Table 2).
8) No correlation was seen between the visual impairment and sex, body weight (Table 4), dose/kg of EB (Table 5), extent of the disease (Table 6), the period from the onset of the disease (Table 7), and diabetes (Table 9). The incidence of visual impairment was higher in the older age groups (Table 3).
9) No significant differen c e was found in the incidence of the side-affects between EB 0.5g per day group and 1.0 g per day group, and between EB 1.0 g once a day group and twice daily group (Table 8).
10) Vitamin B1 was u s ed in all the cases as treatment for the side-affects, and in 6 cases vitamin B12 treatment was added. The effectiveness of these vitamins for visual impairment was not clear, and we presume that the recovery of visual impairment was quite probable only by stopping EB at a right time.抄録全体を表示PDF形式でダウンロード (993K) -
長沢 潤, 本堂 五郎, 福原 徳光, 島尾 忠男, 青柳 昭雄, 山口 智道, 松宮 恒夫, 村田 彰, 吉沢 久雄1970 年 45 巻 1 号 p. 27-36
発行日: 1970年
公開日: 2011/05/24
ジャーナル フリーCases who failed to show negative conversion of tubercle bacilli by primary drugs treatment and had not been treated previously with secondary drugs were divided randomly into two. groups. One group was treated with kanamycin (KM), ethionamide (TH) and cycloserine (CS) and the other with KM, TH and ethambutol (EB). At the beginning of the treatment, the number of cases treated with KM, TH and CS were 35, and the cases treated with KM, TH and EB were 42. (Table 1)抄録全体を表示PDF形式でダウンロード (1029K) -
1970 年 45 巻 1 号 p. 54
発行日: 1970年
公開日: 2011/05/24
ジャーナル フリーPDF形式でダウンロード (120K)
- |<
- <
- 1
- >
- >|